**Supplementary Materials: Effectiveness of a Pharmacogenetic Tool at Improving Treatment Efficacy in Major Depressive Disorder: A Meta-Analysis of Three Clinical Studies**

Silvia Vilches, Miquel Tuson, Eduard Vieta, Enric Álvarez and Jordi Espadaler

Table S1. List of genes and polymorphisms analyzed.

| Gene symbol | Gene name | Polymorphisms |
|-------------|-----------|---------------|
| ABCB1       | ATP binding cassette subfamily B member 1 | rs2235048, rs11983225 |
| AKTI        | V-akt murine thymoma viral oncogene homolog 1 | rs1130214 |
| BDNF        | Brain-derived neurotrophic factor | rs6265 |
| CACNG2      | Calcium channel, voltage-dependent, gamma subunit 2 | rs2284017 |
| CES1        | Carboxylesterase 1 | rs71647871 |
| COMT        | Catechol-O-methyltransferase | rs4680 |
| CRHR1       | Corticotropin releasing hormone receptor 1 | rs4792888 |
| CYPIA2      | Cytochrome P450 family 1 subfamily A member 2 | *1, *1F |
| CYPIB6      | Cytochrome P450 family 2 subfamily B member 6 | *1, *6 |
| CYPIC19     | Cytochrome P450 family 2 subfamily C member 19 | *1, *2, *3, *5, *7, *8, *17, *27 |
| CYPIC29     | Cytochrome P450 family 2 subfamily C member 9 | *1, *2, *3, *6, *8, *27 |
| CYPIE6      | Cytochrome P450 family 2 subfamily D member 6 | *1, *2, *3, *4, *5, *6, *7, *8, *9, *10, *11, *12, *14, *15, *17, *19, *20, *29, *30, *35, *40, *41, *69, *1xN, *2xN, *35X2 |
| CYPIA4      | Cytochrome P450 family 3 subfamily A member 4 | *1, *22 |
| DDI4        | DNA damage inducible transcript 4 | rs1053639 |
| DRD3        | Dopamine receptor D3 | rs963468 |
| EPHX1       | Epoxide hydrolase 1, microsomal (xenobiotic) | rs1051740 |
| FCHSD1      | FCH and double SH3 domains 1 | rs456998 |
| GRIK2       | Glutamate receptor, ionotropic, kainate 2 | rs2518224 |
| GRIK4       | Glutamate receptor, ionotropic kainate 4 | rs1954787 |
| HLA-A       | Major histocompatibility complex, class I, A | rs1061235 |
| HTR1A       | 5-HT (serotonin) receptor 1A, G protein-coupled | rs10042486 |
| HTR2A       | 5-HT (serotonin) receptor 2A, G protein-coupled | rs6311, rs6314, rs9316233 |
| HTR2C       | 5-HT (serotonin) receptor 2C, G protein-coupled | rs1414334 |
| LPHN3       | Latrophilin 3 | rs6551665 |
| NEFM        | Neurofilament, medium polypeptide | rs1379357, rs1457266 |
| OPRM1       | Opioid receptor, mu 1 | rs1799971 |
| RGS4        | Regulator of G-protein signaling 4 | rs2661319 |
| RPTOR       | Regulatory associated protein of MTOR, complex 1 | rs7211818 |
| SLC6A4      | Solute carrier family 6 (neurotransmitter transporter), member 4 | 5-HTTLPR |
| UGT2B15     | UDP glucuronosyltransferase 2 family, polypeptide B15 | rs1902023 |
**Figure S1.** Example of a Neuropharmagen® pharmacogenomics interpretative report for one de-identified study subject, showing (a) the color-coding classification of drugs and (b) detailed information for one of the drugs.